LABU — Direxion Daily S&P Biotech Bull 3X Shares
Data updated: 2026-06-29
LABU — Direxion Daily S&P Biotech Bull 3X Shares data: holdings, portfolio allocation, expenses, performance, cashflows, risk and SEC filings. Leveraged · $518.89M AUM · 0.93% expense ratio · 193.9% 1-yr return. From SEC regulatory filings.
LABU Fund Overview
LABU — Direxion Daily S&P Biotech Bull 3X Shares is a US ETF managed by Direxion Shares ETF Trust, categorised as Leveraged. ABC INVEST provides holdings, performance, costs, cashflows, risk data, prospectus documents and SEC filings, sourced from SEC filings.
- Type: US ETF
- Manager: Direxion Shares ETF Trust
- Category: Leveraged
- Assets under management: $518.89M
- 1-year return: 193.9%
- Ticker: LABU
- SEC CIK: 0001424958
- SEC series ID: S000049373
- Share class ID: C000156149
LABU Holdings
Top 10 holdings of Direxion Daily S&P Biotech Bull 3X Shares by percentage of net assets, from the fund's latest SEC N-PORT filing.
| Holding | % of net assets |
|---|---|
| Dreyfus Government Cash Manage | 7.90% |
| Goldman Financial | 6.66% |
| Goldman Sachs Liq Es Fd A | 1.82% |
| Apellis Pharmaceuticals Inc | 1.53% |
| Revolution Medicines Inc | 1.35% |
| Travere Therapeutics Inc | 1.33% |
| Arrowhead Pharmaceuticals, Inc. | 1.18% |
| Twist Bioscience Corporation | 1.17% |
| Summit Therapeutics Inc. | 1.15% |
| Alkermes PLC | 1.14% |
LABU Portfolio Allocation
Asset-class allocation of Direxion Daily S&P Biotech Bull 3X Shares by percentage of net assets, from the latest SEC N-PORT filing.
| Asset class | Allocation |
|---|---|
| Equity | 82.2% |
| Cash & Equivalents | 16.4% |
| Derivatives | 7.7% |
LABU Performance
Total returns for LABU (as of 2026-08-01), from SEC filings.
| Period | Total return |
|---|---|
| YTD | 11.4% |
| 1 year | 193.9% |
| 3 years (annualised) | 17.2% |
| 5 years (annualised) | -35.2% |
LABU Risk Information
Risk metrics for LABU, derived from monthly returns in SEC filings.
- 1-year volatility (annualised): 57.7%
LABU Costs and Fees
LABU costs about $93 per $10,000 invested per year in fund expenses.
- Net expense ratio: 0.93%
- Gross expense ratio: 0.93%
- Portfolio turnover: 179%
- Brokerage commissions: 34.00 bps of average net assets (SEC N-CEN)
LABU Cashflows
Over the 12 months to 2026-04, Direxion Daily S&P Biotech Bull 3X Shares had net outflows of $927.58M, from monthly SEC N-PORT filings.
| Month | Net flow |
|---|---|
| 2026-04 | −$78.14M |
| 2026-03 | $12.09M |
| 2026-02 | −$43.93M |
| 2026-01 | −$200.17M |
| 2025-12 | −$108.74M |
| 2025-11 | −$126.95M |
LABU Debt Constituents
No individual debt constituents are reported in Direxion Daily S&P Biotech Bull 3X Shares's latest SEC N-PORT filing.
LABU Prospectus and SEC Filings
Official Direxion Daily S&P Biotech Bull 3X Shares filings on SEC EDGAR — prospectus, portfolio holdings and annual reports.
Related Funds
Other Leveraged funds tracked on ABC INVEST:
Data Sources
ABC INVEST compiles this page from public filings made to the U.S. Securities and Exchange Commission (SEC) through EDGAR: portfolio holdings and monthly cashflows from Form N-PORT, expenses and returns from fund prospectuses (Form 485BPOS) and the SEC DERA Risk/Return Summary data sets, annual data from Form N-CEN, and shareholder reports from Form N-CSR.